Abstract
Antitumorous treatment has a number of undesirable side effects including cardiac toxicity. The authors deal with cardiotoxicity monitoring in acute leukemia patients.
In addition to standard methods, they make use of new biochemical markers of heart damage (NT-proBNP, cTnT). Fifteen adult patients with acute leukemia participated in this study.
All patients underwent conventional chemotherapy with anthracyclines, preparatory regimen (a high dose chemotherapy which contains Cyclophosphamide) and haemopoietic stem cell transplantation. The study verified the necessity for monitoring cardiac functions both during the treatment and the follow-up period.